PCV72 COST-EFFECTIVENESS OF EXTENDED-RELEASE NICOTINIC ACID/ LAROPIPRANT AS MONOTHERAPY VERSUS EZETIMIBE MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDAEMIA IN SCOTLAND
Abstract
Authors
K Jameson GM Davies BM Ambegaonkar V Sazonov C ORegan